Truist Securities Reiterates Buy on Elevance Health, Raises Price Target to $600
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald has reiterated a Buy rating on Elevance Health (NYSE:ELV) and increased the price target from $580 to $600.

April 19, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reiterated a Buy rating on Elevance Health and raised the price target from $580 to $600.
The reiteration of a Buy rating combined with an increased price target typically signals a strong bullish outlook from the analyst. This endorsement from a reputable financial analyst like David Macdonald could lead to increased investor confidence in Elevance Health, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100